News coverage about Flex Pharma (NASDAQ:FLKS) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Flex Pharma earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an impact on the company’s share price in the next several days.
A number of equities analysts have recently commented on the stock. Jefferies Group LLC dropped their price target on shares of Flex Pharma from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, May 4th. Zacks Investment Research lowered shares of Flex Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, May 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. Flex Pharma currently has an average rating of “Buy” and an average price target of $15.40.
Flex Pharma (FLKS) opened at 3.63 on Wednesday. The company’s 50-day moving average is $3.64 and its 200-day moving average is $4.23. The company’s market cap is $61.82 million. Flex Pharma has a 12 month low of $3.01 and a 12 month high of $12.76.
Flex Pharma (NASDAQ:FLKS) last posted its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.13. Flex Pharma had a negative return on equity of 60.50% and a negative net margin of 3,043.70%. The business had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.38 million. On average, equities research analysts anticipate that Flex Pharma will post ($2.65) earnings per share for the current year.
WARNING: This piece was first reported by BBNS and is owned by of BBNS. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://baseballnewssource.com/markets/flex-pharma-flks-receiving-somewhat-favorable-press-coverage-accern-reports/1180263.html.
Flex Pharma Company Profile
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Receive News & Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related companies with our FREE daily email newsletter.